An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Fields of Study & Subjects
Renal Diseases and Glomerulopathies
Renal Transplantation Outcomes and Treatments
Chronic Kidney Disease and Diabetes
Publication details
- Journal / source
- Vivli
- Publication date
- 27 March 2026
- Language
- EN
- Document type
- Dataset